TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05192330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses
Description: After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale (pain) were applied to both groups by face to face interview during the day giving appointment for intrauterine insemination. Immediately after the questionnaires were answered, virtual reality glasses were given by the nurse researcher to intervention group for 30 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch
Description: After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS (pain) scoring scale were applied to both groups by face to face interview during the day giving appointment for intrauterine insemination. Immediately after the questionnaires were answered, therapeutictouch were given by the nurse researcher to intervention group for 30 minutes.
Study: NCT04753788

Intervention type: DIAGNOSTIC_TEST
Intervention: PCR
Description: qPCR for T.pallidum

Intervention type: DIAGNOSTIC_TEST
Intervention: LAMP
Description: LAMP assay for T.pallidum
Study: NCT05778513

Intervention type: OTHER
Intervention: Passive knee flexion-extension + Cycle ergometer exercise + 3-week body weight reduction program
Description: Passive knee flexion-extension movements + Incremental cycle ergometer exercise + Multidisciplinary body weight reduction program with a duration of 3 weeks

Intervention type: OTHER
Intervention: Passive knee flexion-extension + Cycle ergometer exercise
Description: Passive knee flexion-extension movements + Incremental cycle ergometer exercise
Study: NCT01872546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUMIRA 40mg
Study: NCT06329947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib 250mg/d qd once daily
Description: mFOLFOX6( Oxaliplatin + Leucovorin + fluorouracil) Oxaliplatin 85mg/m2 d1+CF 400mg/m2 d1+5-FU 400mg/m2d1 /2400mg/m2 continuous intravenous injection (civ) for 46h, The drug is administered every 14 days for a total of 8-12 cycles.
Study: NCT05406349

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-navigation task
Description: Participants will perform a self-navigation task with two experimental conditions: Either they will be asked to walk towards a visible wall-mounted sign, or they will be asked to find and learn a hidden target location within the experimental room.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Observation task
Description: Participants will sit on a chair in a corner of the room (RNS participants) or watch a video that was recorded from the corner of the room (EMU participants). They will be asked to keep track of another person's location who is walking around the room, and to press a button whenever the other person crosses a previously-learned target location.
Study: NCT05108571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5210 10/1000mg
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5210 10/1000mg
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5210-R 10/1000mg
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5210-R 10/1000mg
Description: single dose administration (one tablet once a day)
Study: NCT06368037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DragonFire Transcatheter Myocardial Radiofrequency Ablation System
Description: The patients with hypertrophic obstructive cardiomyopathy were treated with a transcatheter myocardial radiofrequency ablation system and its guiding system under the guidance of echocardiography
Study: NCT06032533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning with Automatic Tourniquet Device
Description: 5 Cycles of Remote Ischemic Conditioning performed on the leg. One cycle consists of 5 minutes of arterial occlusion followed by 5 minutes of reperfusion. The above is repeated daily for 14 days or until patient is discharged.~Patients are randomized to either active Remote Ischemic Conditioning or Sham-treatment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Remote Ischemic Conditioning with Automatic Tourniquet Device
Description: 5 Cycles of sham-treatment performed on the leg. One cycle consists of 5 minutes of sham-treatment followed by 5 minutes of pause. The above is repeated daily for 14 days or until patient is discharged.~Patients are randomized to either active Remote Ischemic Conditioning or Sham-treatment.
Study: NCT05962879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience Training for Teens
Description: A brief 6-session group-based behavioral intervention for high school aged teenagers at risk of a mental illness.
Study: NCT05339802

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 9MW1411 injection 1 combined with Linezolid
Description: After randomization, 9MW1411 injection, single dose, intravenous infusion, linezolid: 600mg, given intravenously or orally every 12 hours, for a total course of treatment not exceeding 14 days.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 9MW1411 injection 2 combined with Linezolid
Description: After randomization, 9MW1411 injection, single dose, intravenous infusion, linezolid: 600mg, given intravenously or orally every 12 hours, for a total course of treatment not exceeding 14 days.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: 9MW1411 injection placebo combined with Linezolid
Description: After randomization, 9MW1411 injection placebo, single dose, intravenous infusion, linezolid: 600mg, given intravenously or orally every 12 hours, for a total course of treatment not exceeding 14 days.
Study: NCT05554809

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strecthing
Description: Comparing the crossover-effect of dynamic versus static stretching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strecthing
Description: Comparing the crossover-effect of dynamic versus static stretching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strecthing
Description: Comparing the crossover-effect of dynamic versus static stretching
Study: NCT05494567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 5mg
Description: patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin for 12 weeks in group 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin Hcl 0.4 mg
Description: patients with BPH/OAB will be treated with combination therapy of tamsulosin plus solifenacin for 12 weeks in group 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin 10 mg
Description: patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin in group 1 and tamsulosin plus solifenacin in group 2 for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin 10 mg
Description: patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin in group 1 and tamsulosin plus solifenacin in group 2 for 12 weeks
Study: NCT04784598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insoles adapted in flip-flop sandals
Description: participants of both groups individually received a pair of customized flip-flop sandals, with or without foot pieces, covered with smooth synthetic leather

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Insoles adapted in flip-flop sandals
Description: participants of both groups individually received a pair of customized flip-flop sandals, with or without foot pieces, covered with smooth synthetic leather
Study: NCT06011122

Intervention type: PROCEDURE
Intervention: Distal radius fracture ORIF with a specific volar plate
Description: Patients who had a distal radius fracture were treated surgically : an ORIF was realised with a volar plate

Intervention type: PROCEDURE
Intervention: Distal radius fracture ORIF with a specific volar plate
Description: Patients who had a distal radius fracture were treated surgically : an ORIF was realised with a volar plate

Intervention type: PROCEDURE
Intervention: Distal radius fracture ORIF with a specific volar plate
Description: Patients who had a distal radius fracture were treated surgically : an ORIF was realised with a volar plate

Intervention type: PROCEDURE
Intervention: Distal radius fracture ORIF with a specific volar plate
Description: Patients who had a distal radius fracture were treated surgically : an ORIF was realised with a volar plate

Intervention type: PROCEDURE
Intervention: Distal radius fracture ORIF with a specific volar plate
Description: Patients who had a distal radius fracture were treated surgically : an ORIF was realised with a volar plate

Intervention type: PROCEDURE
Intervention: Distal radius fracture ORIF with a specific volar plate
Description: Patients who had a distal radius fracture were treated surgically : an ORIF was realised with a volar plate
Study: NCT05983874

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) Dosage
Description: 100µg Month 0 and Month 3
Study: NCT05826262

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diagnostic laparoscopy
Description: diagnosis and management of patients with penetrating anterior abdominal wall injuries
Study: NCT05020925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Intravenous (IV) on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: Famitinib, po, qd
Study: NCT06518343

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine + Pomegranate extract
Description: Participants will consume 1.5 grams L-carnitine with 1.6 grams pomegranate extract at one visit during one intervention period

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-carnitine + Microcrystalline cellulose
Description: Participants will consume 1.5 grams L-carnitine with 1.5 grams microcrystalline cellulose at one visit during one intervention period
Study: NCT06334991

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 t-haNK
Description: CD19t-haNK erived from the parental NK-92 (aNK) cell line, CD19 t-haNK is a human, allogeneic, NK cell line that has been engineered to express a CAR targeting CD19. Similar to the haNK cell line, CD19 t haNK has also been engineered to produce endoplasmic reticulum-retained IL 2 and the high-affinity (158V) variant of the Fcγ receptor (FcγRIIIa/CD16a), and thereby has enhanced CD16-targeted ADCC capabilities. CD19 t-haNK is similar to PD L1 t-haNK, differing only in the CAR that is expressed (CD19 vs PD-L1).~Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. Rituximab has an approximate molecular weight of 145 kD and has a binding affinity for the CD20 antigen of approximately 8.0 nM.
Study: NCT05819034

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scoliosis-Specific Exercise Program
Description: Adolescents in the control group will receive a scoliosis-specific exercise program which will be prescribed to control the progression of the scoliotic curve. This exercise program will include frontal plane active or passive correction exercises for scoliotic posture. The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.~The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scoliosis-Specific Exercise Program
Description: Adolescents in the control group will receive a scoliosis-specific exercise program which will be prescribed to control the progression of the scoliotic curve. This exercise program will include frontal plane active or passive correction exercises for scoliotic posture. The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.~The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft orthoses with external strapping.
Description: Adolescents in the experimental group will receive a scoliosis-specific exercises program which will be prescribed to control the progression of the scoliotic curve in addition to wearing the soft orthoses with external strapping. The wearing schedule of the soft orthosis with the external strapping for every participant in this group will be 12 hours daily for 12 successive weeks.
Study: NCT06572605

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EMD-EBRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image Guided Biopsy
Description: Undergo image-guided EMD biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Given SC
Study: NCT06536465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REC-3964
Description: REC-3964 given at a dose of either 500 mg q12h or 250 mg q12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REC-3964
Description: REC-3964 given at a dose of either 500 mg q12h or 250 mg q12h
Study: NCT06210594

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mupirocin + Nozin + chlorhexidine gluconate
Description: Education/household supplies + antibiotic + antiseptic regimen

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education + Household supplies
Description: Education/household supplies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education + Household supplies
Description: Education/household supplies
Study: NCT04537299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: \~20 mg/kg/day oral, NG or D tube course for 2 consecutive days twice (Days 0 \& 1 and Days 8 \& 9)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo looks exactly like the treatment drug, but it contains no active ingredient
Study: NCT06367309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended totally extraperitoneal repair
Description: The anterior rectus sheath is incised and the retromuscular space is entered through the rectus muscle fibres. The capnopreperitoneum is established and blunt dissection of the retromuscular space is performed. Two additional laparoscopic ports are established 8-10cm lateral to the linea alba caudally to the initial port. The medial border of the rectus sheath is incised and the preperitoneal space below the linea alba is dissected. The hernia orifice is also dissected from peritoneum and preperitoneal fatty tissue. The medial border of the right retromuscular space is then incised and blunt dissection is performed. The hernia orifice is closed with barbed suture and a synthetic mesh is placed on the posterior sheath of the dissected space (intended Mesh-defect ratio 16). The mesh is fixed non-traumatically using glubran glue or no fixation at all.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal onlay mesh
Description: Capnoperitoneum is established through left sided subcostal Veress-Needle punction. Three laparoscopic ports are placed 8-10cm lateral to the linea alba usually on the patient's left side. The peritoneum is incised and detached from the umbilical and supraumbilical linea alba. The peritoneum including the hernia sac and preperitoneal fat is resected. The hernia orifice is then closed using a barbed suture. A coated mesh is than placed to the ventral abdominal wall covering the closed hernia orifices (intended mesh-defect-ratio: 16). The mesh is fixed with two transfacial absorbable sutures and several absorbable tackers placed in double crown technique around the hernia orifice. The capnoperitoneum is released, the trocars removed and the fascia closed with an absorbable suture. The skin is sutured with absorbable sutures.
Study: NCT04714268

Intervention type: PROCEDURE
Intervention: Aorto-iliac endovascular procedure
Description: Percutaneous procedure with stent placement

Intervention type: PROCEDURE
Intervention: Aorto-iliac endovascular procedure
Description: Percutaneous procedure with stent placement
Study: NCT06252025

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Memo-gration
Description: This study tailored a variety of instructional material within each virtual scenario, taking into account various memory triggers. Guidance is activated when the user is identified as making physical contact with an object or discussing a specific keyword. This encompasses textual assistance provided within the virtual environment, the display of multimedia information, and the provision of organized voice guidance. Following the system's instructions, users engaged in discussion with the caregiver, and had the freedom to terminate the conversation at their discretion and explore other topics by interacting with different items.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Picture reminiscence therapy
Description: Picture reminiscence therapy
Study: NCT06486480

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Using robot assisted endoscopy to clear intraventricular hemorrhage
Description: More advanced surgical auxiliary instruments are used to improve surgical accuracy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Using robot assisted endoscopy to clear intraventricular hemorrhage
Description: More advanced surgical auxiliary instruments are used to improve surgical accuracy
Study: NCT05552781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H002 capsule
Description: Small molecule, Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H002 capsule
Description: Small molecule, Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H002 capsule
Description: Small molecule, Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H002 capsule
Description: Small molecule, Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H002 capsule
Description: Small molecule, Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H002 capsule
Description: Small molecule, Capsule
Study: NCT05802160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Good Start Matters - Parenting intervention
Description: The Good Start Matters - Parenting intervention is a 2-month mobile-Health (mHealth) parenting program that aims to improve parenting practices and child health behaviors among British Columbian families of preschoolers. This intervention uses a familial approach and blends the best practices and evidence to promote positive parenting regarding 3 main areas: nutrition, physical activity, and screen-time; which altogether aim to support the development of healthy habits among young children. The mHealth app releases new material on a weekly basis and participants' engagement with the app takes about 30 minutes per week.
Study: NCT05548062

Intervention type: OTHER
Intervention: Hydroxyurea
Description: Prospective observational study. There is no treatment allocation. Patients prescribed with Hydroxyurea are eligible to enroll into this study.

Intervention type: OTHER
Intervention: Ruxolitinib
Description: Prospective observational study. There is no treatment allocation. Patients prescribed with Ruxolitinib are eligible to enroll into this study.
Study: NCT06517719

Intervention type: OTHER
Intervention: lutetium (177Lu) vipivotide tetraxetan
Description: This is an observational study. There is no treatment allocation. The decision to initiate lutetium vipivotide tetraxetan will be based solely on clinical judgement.
Study: NCT06451874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Power Training (FPT)
Description: Participants will receive twice weekly FPT, a progressive functional-based exercises that target optimizing leg force production and leg velocity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Power Training (FPT)
Description: Participants will receive twice weekly FPT, a progressive functional-based exercises that target optimizing leg force production and leg velocity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music-Based Digital Therapy (MBDT)
Description: Participants will receive twice weekly MBDT, a technology-driven gait training that is grounded in evidence-based rehabilitation treatment, rhythmic auditory stimulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music-Based Digital Therapy (MBDT)
Description: Participants will receive twice weekly MBDT, a technology-driven gait training that is grounded in evidence-based rehabilitation treatment, rhythmic auditory stimulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FPT + MBDT
Description: For non-responders who were randomized to augment treatment, they will receive combined FPT and MBDT treatment.
Study: NCT06677307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRRO-110
Description: KRRO-110 drug product, IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KRRO-110
Description: KRRO-110 drug product, IV
Study: NCT05936710

Intervention type: DEVICE
Group type: OTHER
Intervention: ACETATE based dialysate
Description: Intermittent hemodialysis with an acetate based dialysate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CITRATE based dialysate
Description: Intermittent hemodialysis with an citrate based dialysate.
Study: NCT05091385

Intervention type: BIOLOGICAL
Intervention: Mepolizumab given SC 100mg every 4 weeks between Dec 2017 and Dec 2019
Description: Mepolizumab administered within the frame of a severe asthma treatment program financed by National Health Fund in Poland for patients fulfilling specific criteria of asthma severity.